Search

Your search keyword '"Siringo, Marco"' showing total 21 results
Start Over Author "Siringo, Marco"
21 results on '"Siringo, Marco"'

1. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Author

Gelibter, Alain, Asquino, Angela, Strigari, Lidia, Zizzari, Ilaria Grazia, Tuosto, Lucrezia, Scirocchi, Fabio, Pace, Angelica, Siringo, Marco, Tramontano, Elisa, Bianchini, Serena, Bellati, Filippo, Botticelli, Andrea, Paoli, Donatella, Santini, Daniele, Nuti, Marianna, Rughetti, Aurelia, and Napoletano, Chiara

Published
2024
Full Text
View/download PDF

2. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

3. Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.

Author

Magri, Valentina, Marino, Luca, Del Giudice, Francesco, De Meo, Michela, Siringo, Marco, De Berardinis, Ettore, Gandini, Orietta, Santini, Daniele, Nicolazzo, Chiara, and Gazzaniga, Paola

Subjects
NON-muscle invasive bladder cancer, TRANSURETHRAL resection of bladder, EXTRACELLULAR vesicles, SURVIVAL rate, PROGNOSIS
Abstract

Non-muscle-invasive bladder cancer (NMIBC) prognosis varies significantly due to the biological and clinical heterogeneity. High-risk stage T1-G3, comprising 15–20% of NMIBCs, involves the lamina propria and is associated with higher rates of recurrence, progression, and cancer-specific mortality. In the present study, we have evaluated the enumeration of tumour-derived extracellular vesicles (tdEVs) and circulating tumour cells (CTCs) in high-risk NMIBC patients and their correlation with survival outcomes such as time to progression (TTP), and cancer-specific survival (CSS). Eighty-three high-risk T1-G3 NMIBC patients treated between September 2010 and January 2013 were included. Blood samples were collected before a transurethral resection of the bladder (TURB) and analysed using the CellSearch® system. The presence of at least one CTC was associated with a shorter TTP and CSS. Extending follow-up to 120 months and incorporating automated tdEV evaluation using ACCEPT software demonstrated that tdEV count may additionally stratify patient risk. Combining tdEVs and CTCs improves risk stratification for NMIBC progression, suggesting that tdEVs could be valuable biomarkers for prognosis and disease monitoring. Further research is needed to confirm these findings and establish the clinical significance of tdEVs in early-stage cancers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors

Author

Magri, Valentina, primary, De Renzi, Gianluigi, additional, Marino, Luca, additional, De Meo, Michela, additional, Siringo, Marco, additional, Gelibter, Alain, additional, Gareri, Roberta, additional, Cataldi, Chiara, additional, Giannini, Giuseppe, additional, Santini, Daniele, additional, Nicolazzo, Chiara, additional, and Gazzaniga, Paola, additional

Published
2024
Full Text
View/download PDF

5. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

6. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Author

Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, and Cortellini, Alessio

Published
2021
Full Text
View/download PDF

7. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.

Author

Gelibter, Alain, Asquino, Angela, Strigari, Lidia, Zizzari, Ilaria Grazia, Tuosto, Lucrezia, Scirocchi, Fabio, Pace, Angelica, Siringo, Marco, Tramontano, Elisa, Bianchini, Serena, Bellati, Filippo, Botticelli, Andrea, Paoli, Donatella, Santini, Daniele, Nuti, Marianna, Rughetti, Aurelia, and Napoletano, Chiara

Subjects
REGULATORY T cells, IMMUNOTHERAPY, PROGNOSIS, T cells, NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors
Abstract

Background: Immune checkpoint inhibitors (ICIs), administered alone or combined with chemotherapy, are the standard of care in advanced non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). Despite these treatments' success, most long-term survival benefit is restricted to approximately 20% of patients, highlighting the need to identify novel biomarkers to optimize treatment strategies. In several solid tumors, immune soluble factors, the activatory CD137+ Tcells, and the immunosuppressive cell subsets Tregs and MDSCs (PMN(Lox1+)-MDSC and M-MDSCs) correlated with responses to ICIs and clinical outcomes thus becoming appealing predictive and prognostic factors. This study investigated the role of distinct CD137+ Tcell subsets, Tregs, MDSCs, and immune-soluble factors in NSCLC patients as possible biomarkers. Methods: The levels of T cells, MDSCs and soluble factors were evaluated in 89 metastatic NSCLC patients who underwent ICIs as first- or second-line treatment. T cell analysis was performed by cytoflurimetry evaluating Tregs and different CD137+ Tcell subsets also combined with CD3+, CD8+, PD1+, and Ki67+ markers. Circulating cytokines and immune checkpoints were also evaluated by Luminex analysis. All these parameters were correlated with several clinical factors (age, sex, smoking status, PS and TPS), response to therapy, PFS , and OS. The analyses were conducted in the overall population and in patients treated with ICIs as first-line (naïve patients). Results: In both groups of patients, high levels of circulating CD137+ and CD137+PD1+ T cells (total, CD4 and CD8) and the soluble factor LAG3 positively correlated with response to therapy. In naïve patients, PMN(Lox1+)-MDSCs negatively correlated with clinical response, and a high percentage of Tregs was associated with favorable survival. Moreover, the balance between Treg/CD137+ Tcells or PMN(Lox1+)-MDSC/CD137+ Tcells was higher in non-responding patients and was associated with poor survival. CD137+ Tcells and Tregs resulted as two positive independent prognostic factors. Conclusion: High levels of CD137+, CD137+PD1+ Tcells and sLAG3 could predict the response to ICIs in NSCLC patients independently by previous therapy. Combining the evaluation of CD137+ Tcells and Tregs also as Treg/CD137+ T cells ratio it is possible to identify naive patients with longer survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

13. Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, additional, Cleary, Siobhan, additional, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Bordi, Paola, additional, Tonini, Giuseppe, additional, Vincenzi, Bruno, additional, Tucci, Marco, additional, Russo, Alessandro, additional, Pantano, Francesco, additional, Russano, Marco, additional, Stucci, Luigia Stefania, additional, Sergi, Maria Chiara, additional, Falconi, Martina, additional, Zarzana, Maria Antonietta., additional, Santini, Daniele, additional, Spagnolo, Francesco, additional, Tanda, Enrica T., additional, Rastelli, Francesca, additional, Giorgi, Francesca Chiara., additional, Pergolesi, Federica, additional, Giusti, Raffaele, additional, Filetti, Marco, additional, Lo Bianco, Francesca, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Gelibter, Alain, additional, Siringo, Marco, additional, Ferrari, Marco, additional, Marconcini, Riccardo, additional, Vitale, Maria Giuseppa., additional, Nicolardi, Linda, additional, Chiari, Rita, additional, Ghidini, Michele, additional, Nigro, Olga, additional, Grossi, Francesco, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Queirolo, Paola, additional, Bracarda, Sergio, additional, Macrini, Serena, additional, Inno, Alessandro, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Spoto, Chiara, additional, Vitale, Maria Grazia., additional, Cannita, Katia, additional, Gennari, Alessandra, additional, Morganstein, Daniel L., additional, Mallardo, Domenico, additional, Nibid, Lorenzo, additional, Sabarese, Giovanna, additional, Brunetti, Leonardo, additional, Perrone, Giuseppe, additional, Ascierto, Paolo A., additional, Ficorella, Corrado, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

14. Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer

Author

Siringo, Marco, Baena, Javier, Bote de Cabo, Helena, Torres Jiménez, Javier, Zurera, María, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis Gonzaga, Siringo, Marco, Baena, Javier, Bote de Cabo, Helena, Torres Jiménez, Javier, Zurera, María, Zugazagoitia, Jon, and Paz-Ares Rodríguez, Luis Gonzaga

Abstract

Despite the use of novel agents in the first-line therapeutic setting, such as PD- 1/PDL1 axis blockers for non-oncogene addicted non-small-cell lung cancer, most patients with advanced disease experience progression will succumb to the illness within a short period of time. Currently, the standard second-line treatment consists primarily of systemic cytotoxic therapies, which typically yield poor outcomes. Recently, several novel therapeutic strategies have emerged that may improve patient outcomes. This article reviews current state-of-the-art treatments in this scenario and highlights potential future options., Immune checkpoint inhibitors (ICIs) have revolutionized the management of non-oncogene addicted non-small-cell lung cancer (NSCLC). Blocking the anti-PD-1 axis represents the current standard of care in the first-line setting, with drugs administered either as monotherapy or in combination with chemotherapy. Despite notable successes achieved with ICIs, most of their longterm benefits are restricted to approximately 20% of patients. Consequently, the post-failure treatment landscape after failure to first-line treatment remains a complex challenge. Currently, docetaxel remains the preferred option, although its benefits remain modest as most patients do not respond or progress promptly. In recent times, novel agents and treatment combinations have emerged, offering fresh opportunities to improve patient outcomes. ICIs combined either with antiangiogenic or other novel immunotherapeutic compounds have shown promising preliminary activity. However, more mature data concerning specific combinations do not support their benefit over standard of care. In addition, antibody–drug conjugates seem to be the most promising alternative among all available compounds according to already-published phase I/II data that will be confirmed in soon-to-bepublished phase III trial data. In this report, we provide a comprehensive overview of the current second-line treatment options and discuss future therapeutic perspectives., Depto. de Medicina, Fac. de Medicina, TRUE, pub, Descuento UCM

Published
2023

16. Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Author

Metro, Giulio, primary, De Giglio, Andrea, additional, Ricciuti, Biagio, additional, Siringo, Marco, additional, Marinelli, Daniele, additional, Gelibter, Alain, additional, Pecci, Federica, additional, Berardi, Rossana, additional, Cantini, Luca, additional, Di Federico, Alessandro, additional, Andrini, Elisa, additional, Mosca, Mirta, additional, Lamberti, Giuseppe, additional, Brambilla, Marta, additional, and Mountzios, Giannis, additional

Published
2022
Full Text
View/download PDF

18. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Author

Buti, Sebastiano, primary, Bersanelli, Melissa, additional, Perrone, Fabiana, additional, Bracarda, Sergio, additional, Di Maio, Massimo, additional, Giusti, Raffaele, additional, Nigro, Olga, additional, Cortinovis, Diego L., additional, Aerts, Joachim G.J.V., additional, Guaitoli, Giorgia, additional, Barbieri, Fausto, additional, Ferrara, Miriam G., additional, Bria, Emilio, additional, Grossi, Francesco, additional, Bareggi, Claudia, additional, Berardi, Rossana, additional, Torniai, Mariangela, additional, Cantini, Luca, additional, Sforza, Vincenzo, additional, Genova, Carlo, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Della Gravara, Luigi, additional, Gori, Stefania, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Filetti, Marco, additional, Citarella, Fabrizio, additional, Russano, Marco, additional, Mazzoni, Francesca, additional, Garassino, Marina C., additional, De Toma, Alessandro, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Siringo, Marco, additional, Follador, Alessandro, additional, Bisonni, Renato, additional, Tuzi, Alessandro, additional, Minuti, Gabriele, additional, Landi, Lorenza, additional, Ricciardi, Serena, additional, Migliorino, Maria R., additional, Tabbò, Fabrizio, additional, Olmetto, Emanuela, additional, Metro, Giulio, additional, Adamo, Vincenzo, additional, Russo, Alessandro, additional, Spinelli, Gian P., additional, Banna, Giuseppe L., additional, Addeo, Alfredo, additional, Friedlaender, Alex, additional, Cannita, Katia, additional, Porzio, Giampiero, additional, Ficorella, Corrado, additional, Carmisciano, Luca, additional, Pinato, David J., additional, Mazzaschi, Giulia, additional, Tiseo, Marcello, additional, and Cortellini, Alessio, additional

Published
2021
Full Text
View/download PDF

19. Additional file 1 of PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Author

Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, and Cortellini, Alessio

Subjects
Data_FILES
Abstract

Additional file 1: Table S1

Published
2021
Full Text
View/download PDF

20. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Author

Cortellini, Alessio, primary, Di Maio, Massimo, additional, Nigro, Olga, additional, Leonetti, Alessandro, additional, Cortinovis, Diego L, additional, Aerts, Joachim GJV, additional, Guaitoli, Giorgia, additional, Barbieri, Fausto, additional, Giusti, Raffaele, additional, Ferrara, Miriam G, additional, Bria, Emilio, additional, D'Argento, Ettore, additional, Grossi, Francesco, additional, Rijavec, Erika, additional, Guida, Annalisa, additional, Berardi, Rossana, additional, Torniai, Mariangela, additional, Sforza, Vincenzo, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Garassino, Marina Chiara, additional, De Toma, Alessandro, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Siringo, Marco, additional, Marchetti, Paolo, additional, Macerelli, Marianna, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Della Gravara, Luigi, additional, Inno, Alessandro, additional, Michele, De Tursi, additional, Grassadonia, Antonino, additional, Di Marino, Pietro, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Filetti, Marco, additional, Santini, Daniele, additional, Citarella, Fabrizio, additional, Russano, Marco, additional, Cantini, Luca, additional, Tuzi, Alessandro, additional, Bordi, Paola, additional, Minuti, Gabriele, additional, Landi, Lorenza, additional, Ricciardi, Serena, additional, Migliorino, Maria R, additional, Passiglia, Francesco, additional, Bironzo, Paolo, additional, Metro, Giulio, additional, Adamo, Vincenzo, additional, Russo, Alessandro, additional, Spinelli, Gian Paolo, additional, Banna, Giuseppe L, additional, Friedlaender, Alex, additional, Addeo, Alfredo, additional, Cannita, Katia, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, and Pinato, David J, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results